Search Results (2)

Since we aim to test new options to find medication for cognitive disorders, we have begun to assess the effect of semaglutide and to conduct a review gathering studies that have attempted this purpose. This systematic review focuses on the cognitive effects of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), in the context of neurological and cognitive impairment. Semaglutide, a synthetic GLP-1 analog, showcased neuroprotective effects beyond metabolic regulation. It mitigated apoptosis and improved cognitive dysfunction in cerebrovascular disease, suggesting broader implications for neurological well-being. Also, studies highlighted GLP-1 RAs’ positive impact on olfactory function in obese individuals with type 2 diabetes, on neurodegenerative disorders, multiple sclerosis, and endotoxemia. In order to analyze current studies that assess the impact of semaglutide on cognitive function, a literature search was conducted up to February 2024 on two online databases, MEDLINE (via PubMed) and Web of Science Core Collection, as well as various websites. Fifteen studies on mice populations and two studies on cell lines were included, analyzed, and assessed with bias-specific tools. The neuroprotective and anti-apoptotic properties of GLP-1 and its analogs were emphasized, with animal models and cell line studies demonstrating enhanced cognitive function. While promising, limitations include fewer studies, highlighting the need for extensive research, particularly in the human population. Even though this medication seems promising, there are significant limitations, one of which is the lack of studies on human subjects. Therefore, this review aims to gather current evidence. Full article

The aim of the study was to investigate if the application of a synthetic olfactory agonist (SOA) would reduce indicators of stress in sows, in response to a stressor prior to parturition, and if it would improve farrowing house performance of sows and their piglets. Two studies were conducted: an intensive study with 47 sows, either having their first or second litter (Control n = 24; SOA n = 23); and a commercial validation study with 418 sows, either having their first litter or have had multiple litters (Control n = 210; SOA n = 208). Within the intensive study, sows were housed with or without a synthetic olfactory agonist suspended in the creep area of the farrowing crate, whereas within the commercial validation study, sows were housed with or without a synthetic olfactory agonist suspended over the adjoining creep area of two farrowing crates. Within the intensive study, despite a discernible increase in cortisol concentration in response to a stressor (snout rope test), cortisol response was not different between treatments (p > 0.05). Farrowing duration in first-litter sows exposed to the SOA was decreased (p < 0.001) whilst there was no impact on farrowing duration in second litter sows. Piglets were not attracted by the SOA to increase their utilisation of the creep area and spent more time in proximity to the sow (p < 0.05). Within the commercial validation study, no impacts were seen on piglet production measures (p > 0.05). Largely the use of an SOA within the farrowing house did not impact the sow or her piglets in either the intensive study or commercial validation study. Based on these current results, the use of SOA within the farrowing house is not supported. Full article